Differential Effects of Typical and Atypical Antipsychotics on MK-801-induced EEG Changes in Rats

  • Kwon, Jee-Sook (Department of Pharmacology, School of Medicine, School of Dentistry, Kyungpook National University) ;
  • Kim, Ki-Min (Department of Pharmacology, School of Medicine, School of Dentistry, Kyungpook National University) ;
  • Chang, Su-Min (Department of Pharmacology, School of Medicine, School of Dentistry, Kyungpook National University) ;
  • Kim, Choong-Young (Department of Pharmacology, School of Medicine, School of Dentistry, Kyungpook National University) ;
  • Chung, Tai-Ho (WHO Collaboration Viral Hepatitis Center, School of Dentistry, Kyungpook National University) ;
  • Choi, Byung-Ju (Deportment of Dental Pharmacology, School of Dentistry, Kyungpook National University) ;
  • Lee, Maan-Gee (Department of Pharmacology, School of Medicine, School of Dentistry, Kyungpook National University)
  • Published : 2005.02.21

Abstract

We examined whether the abnormal EEG state by NMDA receptor blocker MK-801 can be reversed by typical and atypical antipsychotics differentially by comparing their spectral profiles after drug treatment in rats. The spectral profiles produced by typical antipsychotics chlorpromazine (5 mg/kg, i.p.) and haloperidol (0.5 mg/kg, i.p.) were differ from that by atypical antipsychotic clozapine (5 mg/kg, i.p.) in the rats treated with or without MK-801 treatment (0.2 mg/kg, i.p.) which produce behavioral abnormalities like hyperlocomotion and stereotypy. The dissimilarity between the states produced by antipsychotics and the control state was examined with the distance of the location of the canonical variables calculated by stepwise discriminant analysis with the relative band powers as input variables. Although clozapine produced more different state from normal state than typical antipsychotics, clozapine could reverse the abnormal schizophrenic state induced by MK-801 to the state closer to the normal state than the typical antipsychotics. The results suggest that atypical anesthetic can reverse the abnormal schizophrenic state with negative symptom to the normal state better than typical antipsychotic. The results indicate that the multivariate discriminant analysis using the spectral parameters can help differentiate the antipsychotics with different actions.

Keywords

References

  1. Ahnaou A, Megens AA, Drinkenburg WH. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 48: 47-54, 2003 https://doi.org/10.1159/000071829
  2. Arvanov VL, Wang RY. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289: 1000-1006, 1999
  3. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283: 226-234, 1997
  4. Bo P, Ongini E, Giorgetti A, Savoldi F. Synchronization of the EEG and sedation induced by neuroleptics depend upon blockade of both D1 and D2 dopamine receptors. Neuropharmacology 27: 799-805, 1988 https://doi.org/10.1016/0028-3908(88)90094-9
  5. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120: 67-74, 1995 https://doi.org/10.1007/BF02246146
  6. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol 449: 121-125, 2002 https://doi.org/10.1016/S0014-2999(02)02041-1
  7. Dimpfel W. Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG). Eur J Med Res 8: 199-207, 2003
  8. Dimpfel W, Otten U. Studies of gangliosides in diverse nerve cell cultures. Adv Exp Med Biol 174: 525-534, 1984
  9. Dimpfel W, Decker H. Classification of sulpiride, clozapine and haloperidol by toposelective recording from different brain structures in the immobilized rat (stereo-EEG). Neuropsychobiology 14: 157-164, 1985 https://doi.org/10.1159/000118220
  10. Dimpfel W, Spuler M, Wessel K. Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology (Berl) 107: 195-202, 1992 https://doi.org/10.1007/BF02245137
  11. Goudie AJ, Smith JA. Discriminative stimulus properties of antipsychotics. Pharmacol Biochem Behav 64: 193-201, 1999 https://doi.org/10.1016/S0091-3057(99)00079-9
  12. Herrmann WM. Electroencephalography in drug research: Gustav Fischer Verlag, 1982
  13. Hollister LE. Antipsychotic agents and lithium. In: Katzung BG ed, Basic and Clinical Pharmacology. 6th ed. Prentice Hall International, London, p 432-447, 1995
  14. Hughes AM, Lynch P, Rhodes J, Ervine CM, Yates RA. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol 48: 323-330, 1999 https://doi.org/10.1046/j.1365-2125.1999.00021.x
  15. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308, 1991 https://doi.org/10.1176/ajp.148.10.1301
  16. Knott V, Labelle A, Jones B, Mahoney C. Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. Schizophr Res 50: 41-53, 2001 https://doi.org/10.1016/S0920-9964(00)00165-1
  17. Koek W, Woods JH, Winger GD. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245: 969-974, 1988
  18. Lim SH, Kwon JS, Kim KM, Park SJ, Park JS, Jeong SH, Lee MG. Basic requirements for spectrum analysis of electroencephalographic effects of central acting drugs. J Appl Pharmacol 8: 63-71, 2000
  19. Martin P, Waters N, Carlsson A, Carlsson ML. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication). J Neural Transm 104: 561-564, 1997 https://doi.org/10.1007/BF01277672
  20. McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 30: 795-803, 1990
  21. Ninan I, Kulkarni SK. Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801. Indian J Physiol Pharmacol 42: 375-382, 1998
  22. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev Neurosci 10: 59-90, 1999
  23. Seeman P, Corbett R, Van Tol HH. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16: 93-110; discussion 111- 135, 1997 https://doi.org/10.1016/S0893-133X(96)00187-X
  24. Smith JA, Boyer-Millar C, Goudie AJ. Does MK-801 discrimination constitute an animal model of schizophrenia useful for detecting atypical antipsychotics? Pharmacol Biochem Behav 64: 429- 433, 1999 https://doi.org/10.1016/S0091-3057(99)00077-5
  25. Tiedtke PI, Bischoff C, Schmidt WJ. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 81: 173-182, 1990 https://doi.org/10.1007/BF01245040
  26. Varty GB, Higgins GA. Examination of drug-induced and isolationinduced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl) 122: 15-26, 1995 https://doi.org/10.1007/BF02246437
  27. Yun JE, Lee MG. Electroencephalographic effects of chlorpromazine in rats. Kor J Physiol Pharmacol 3: 245-250, 1999
  28. Zhang W, Pouzet B, Jongen-Relo AL, Weiner I, Feldon J. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics. Neuroreport 10: 2533-2538, 1999 https://doi.org/10.1097/00001756-199908200-00018